PH12014501601A1 - Artemisinin-based combination therapy for treating viral mediated disease - Google Patents

Artemisinin-based combination therapy for treating viral mediated disease

Info

Publication number
PH12014501601A1
PH12014501601A1 PH12014501601A PH12014501601A PH12014501601A1 PH 12014501601 A1 PH12014501601 A1 PH 12014501601A1 PH 12014501601 A PH12014501601 A PH 12014501601A PH 12014501601 A PH12014501601 A PH 12014501601A PH 12014501601 A1 PH12014501601 A1 PH 12014501601A1
Authority
PH
Philippines
Prior art keywords
artemisinin
combination therapy
individual
effective amount
act
Prior art date
Application number
PH12014501601A
Other languages
English (en)
Inventor
Steele Robert Lewis
Musso Anthony Fedele
David D Mundschenk
De Casteele Van Russell
Original Assignee
Kryptonite Group Ltd
Steele Robert Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/201,749 external-priority patent/US20140256762A1/en
Application filed by Kryptonite Group Ltd, Steele Robert Lewis filed Critical Kryptonite Group Ltd
Publication of PH12014501601A1 publication Critical patent/PH12014501601A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12014501601A 2013-09-17 2014-07-11 Artemisinin-based combination therapy for treating viral mediated disease PH12014501601A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361878848P 2013-09-17 2013-09-17
US14/201,749 US20140256762A1 (en) 2012-07-06 2014-03-07 Artemisinin-based combination therapy for treating viral mediated disease
PCT/US2014/033556 WO2015041723A1 (fr) 2013-09-17 2014-04-09 Thérapie combinée à base d'artémisinine utilisable en vue du traitement de maladies à médiation virale

Publications (1)

Publication Number Publication Date
PH12014501601A1 true PH12014501601A1 (en) 2015-09-14

Family

ID=50928251

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501601A PH12014501601A1 (en) 2013-09-17 2014-07-11 Artemisinin-based combination therapy for treating viral mediated disease

Country Status (2)

Country Link
PH (1) PH12014501601A1 (fr)
WO (2) WO2015041722A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2722981C1 (ru) * 2019-12-31 2020-06-05 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Способ лечения малярии с помощью терапевтической комбинации ингибиторов теломеразы (иматиниба мезилат) и артеметера
US20230114854A1 (en) 2020-02-14 2023-04-13 Cellgentek Co., Ltd. Chimeric antigen receptor targeting b-cell maturation antigen and use thereof
WO2022128920A2 (fr) * 2020-12-14 2022-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de médicaments qui rigidifient des gamétocytes matures pour bloquer la transmission de parasites de plasmodium

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225427A (en) 1988-10-04 1993-07-06 Hoechst Aktiengesellschaft 10-substituted ether derivatives of dihydroartemisinin, process for their preparation and their use as antiprotozoal agents
US5225562A (en) 1990-08-10 1993-07-06 Mcchesney James D Method of preparing (+)-deoxoartemisinin and selected analogues of (+)-deoxoartemisinin
US5677468A (en) 1995-06-29 1997-10-14 Hauser, Inc. Artemisinin dimer compounds having anticancer activity
USRE38117E1 (en) 1995-06-29 2003-05-06 Hauser, Inc. Trioxane dimer compound having antiproliferative and antitumor activities
US6136847A (en) 1996-12-02 2000-10-24 Johns Hopkins University Water-soluble trioxanes as potent and safe antimalarial agents
CH692321A5 (de) 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
US6160004A (en) 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
US6127405A (en) 1998-07-10 2000-10-03 Council Of Scientific And Industrial Research Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent
UA75325C2 (en) 1998-07-14 2006-04-17 Bayer Ag Antiparasitic derivatives of artemisin (endoperoxides)
WO2000004026A1 (fr) 1998-07-14 2000-01-27 The Hong Kong University Of Science & Technology Derives de trioxane
US6126038A (en) 1998-10-30 2000-10-03 Olegnowicz; Israel Atomizing pump spray
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
GB2360517B (en) 2000-03-24 2004-09-01 Council Scient Ind Res An improved process for the preparation of arteethers from dihydroartemisinin
WO2003068736A2 (fr) 2002-02-09 2003-08-21 U.S. Army Medical Research And Material Command Composes melanges de steroides 1,2,4,5-tetraoxane et procedes de fabrication associes
US6861066B2 (en) 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6683193B2 (en) 2002-03-25 2004-01-27 Council Of Scientific And Industrial Research Single pot conversion of artemisinin into artemether
US6685972B2 (en) 2002-03-25 2004-02-03 Council Of Scientific And Industrial Research Process for isolating artemisinin from Artemisia annua
US6737438B2 (en) 2002-03-28 2004-05-18 Council Of Scientific And Industrial Research Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof
US6906205B2 (en) 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6790863B2 (en) 2002-10-15 2004-09-14 University Of Mississippi Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents
US6750356B1 (en) 2002-12-02 2004-06-15 Council Of Scientific And Industrial Research Single pot conversion of artemisinin into arteether
AP2006003557A0 (en) * 2003-09-04 2006-04-30 Cipla Ltd Antimalarial compositions and process thereof.
US7071226B1 (en) 2004-12-28 2006-07-04 Council Of Scientific And Industrial Research Amino-functionalized 1,2,4-trioxanes useful as antimalarial agents and process for preparation thereof
US20130071474A1 (en) * 2009-04-22 2013-03-21 James Spencer COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES
US20140011830A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Parasitic Mediated Disease
CA2853701A1 (fr) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Compositions a base d'artemisinine et de berberine et leurs procedes de fabrication
US20140011829A1 (en) * 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease

Also Published As

Publication number Publication date
WO2015041723A1 (fr) 2015-03-26
WO2015041722A1 (fr) 2015-03-26

Similar Documents

Publication Publication Date Title
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
WO2009123776A3 (fr) Médicaments antiviraux pour le traitement d'une infection par un arénavirus
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
WO2013123215A3 (fr) Médicaments antiviraux pour le traitement d'infections à arénavirus
EA202090258A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
EA201490254A1 (ru) Комбинированное лечение гепатита с
NI201100194A (es) Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX340985B (es) Compuestos de n-heteroarilo.
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
IN2013CH05288A (fr)
PH12014501600A1 (en) Enhanced artemisinin-based combination therapy for treating parasitic mediated disease